EUCTR2011-002640-27-DE进行中（未招募）不适用
A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn?s disease (Ileo-Colitis) - I.G.O.N. 1 STUDY
GIULIANI0 个研究点目标入组 160 人开始时间: 2012年8月23日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent, personally signed and dated by the patient prior any study-related procedures is carried out. 2. Male and female outpatients aging 18-75 years old. 3. Female patients not of childbearing potential (women in menopause defined as surgically sterile or one year postmenopausal); female patients of childbearing potential upon negative pregnancy testing at screening and using highly effective contraception (Pearl Index < 1) during the study. 4. Patients with Crohn’s disease in the active phase at screening visit (the activity is defined using the Crohn’s disease Activity Index (CDAI) according to the European guidelines). 5. Crohn’s disease limited to terminal ileum and/or right colon,.that has been documented by instrumental information on localization and extension according to inclusion criteria 9. . 6. Patients with a CDAI score of >220 and =400 for at least one week prior to enrollment. 7. No treatment with biologics (e.g.:infliximab, adalimumab, or natalizumab), in the 90 days prior the enrolment. 8. Patients with steroid resistance or steroid dependence, defined according to the ECCO consensus document 9. Absence of Strictures with pre-stenotic dilatation documented by ultrasonography or Rx or NMR, performed within 1 year prior to the enrollment 10. Ability to understand and comply with study procedures and restrictions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Pregnant or breast-feeding women. 2. Patients with Ulcerative Colitis. 3. Patients with Crohn’s disease involving the stomach and/or the proximal small intestine, or patients with lesions confined to the transverse or left colon as assessed by standard clinical criteria. 4. Patients treated with biologics(e.g.:infliximab, adalimumab, or natalizumab), in the 90 days prior the enrolment. 5. Patients in treatment with a standard dose of immunomodulators (e.g.: azathioprine, mercaptopurine, methotrexate) maintained stably for less than 6 months (patients treated with a stable dose for at least 6 months are eligible).The standard doses, according to ECCO consensus document, are 2-2.5 mg/kg/day for azathioprine and 1-1.5 mg/kg/day for mercaptopurine. 6. Oral and/or systemic antibiotic treatment within 3 weeks before screening. 7. Presence of local complications (e.g. abscesses, strictures and fistulae), and/or extra-
- •intestinal manifestations (arthritis or arthralgia, iritis or uveitis, erythema nodosum,or phyoderma gangrenosum or aphthous stomatitis, fever >37.8°C) dysplasia and malignancies. 8. A history of colon surgery performed within the past 12 months prior to first dose or an ileal resection more than 70 cm in the past. 9. Strictures with pre-stenotic dilatation. 10. Presence of stoma or ileo-recto-anastomosis. 11. Screening laboratory values within the following parameters: ? APTT > 1.5 ULN ? plateletcount =100,000 /mm3 ? serum creatinine >1.5 ULN ? total bilirubin >1.5 ULN (excluding Gilbert Syndrome) ? AST and ALT >1.5 ULN. 12. QTc interval >450 msec for males and >470 msec for females. 13. Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, including infections, malignancy, medical disorder that may require treatment (e.g. renal or hepatic impairment) or that make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures. 14. History of alcohol or other drug abuse within the last year. 15. Patients potentially presenting poor reliability (e.g. bad mental conditions). 16. Known hypersensitivity to oligonucleotides or any ingredient in the study products. 17. Patients who used another investigational agent or who took part in a clinical trial within the last 6 months prior first dose.
研究者
相似试验
进行中（未招募）
不适用
A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn’s disease (Ileo-Colitis)ACTIVE CROHN'S DISEASEMedDRA version: 14.1Level: LLTClassification code 10021315Term: Ileitis terminalSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-002640-27-ITGIULIANI
进行中（未招募）
1 期
A Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)EUCTR2019-003524-20-ITF. HOFFMANN - LA ROCHE LTD.105
进行中（未招募）
不适用
A Phase II multicenter, randomized, double-blind, placebo-controlled, dose ranging, parallel group study of the safety and efficacy of the oral Neurokinin-1 Receptor Antagonist, GW679769, when administered as 50 mg, 100 mg, and 150 mg oral tablets in combination with Ondansetron Hydrochloride and Dexamethasone for the rrevention of chemotherapy-induced nausea and vomiting in cancer subjects receiving moderately emetogenic chemotherapy.Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)EUCTR2004-001020-20-DEGlaxoSmithKline Research & Development Ltd.708
进行中（未招募）
不适用
A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in remission.EUCTR2011-005678-47-ITGIULIANI
进行中（未招募）
不适用
A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with open label nicotine replacementMale or female subjects who are chronic smokers, but motivated to quit smoking will be recruited.EUCTR2008-002472-99-DEEvotec Neurosciences GmbH